The advanced protocol covers all major senescent cell survival pathways (BCL-2, BCL-XL, BCL-W, src kinase via natural or pharmaceutical agents) alongside daily autophagy maintenance and NAD+ optimization. Designed for individuals over 50 with 3+ months of senolytic experience who want the most comprehensive evidence-based cellular aging intervention available.

The natural components (fisetin, quercetin, spermidine, NMN) are well-tolerated at these doses. The pharmaceutical component (dasatinib) requires physician oversight and monitoring. Full protocol should be reviewed with a longevity physician.

What results can I expect from the advanced protocol vs beginner?

Greater biomarker reductions (hsCRP, IL-6, p16) and potentially faster functional improvement than single-agent approaches. No comparative human data exists, but the mechanistic coverage is substantially broader.